1st TAVR Comparison Trial Favors Sapien XT Over CoreValve

With two units now approved for transcatheter aortic valve substitute (TAVR), the marketing battle has begun to win the hearts and minds of cardiologists. On Saturday at the ACC, Medtronic acquired bragging rights exhibiting the 1st mortality advantage for its CoreValve gadget. A equivalent improvement did not arise in the Companion trials with the Edwards Sapien gadget, but all the professionals have warned against cross-trial comparisons. Now an actual randomized trial has emerged evaluating the two platforms. The outcomes favor the Sapien XT, but the size and scope of the trial imply that the discussion and debate will definitely carry on.

Selection, presented at the American School of Cardiology meeting in Washington, DC, and published simultaneously in JAMA, was an investigator-initiated trial in which 241 sufferers with significant aortic stenosis had been randomized to the Edwards Sapien XT or the Medtronic CoreValve at 5 centers in Germany. The primary endpoint was gadget accomplishment, defined as implantation of the gadget in the right position with minor or no regurgitation.

Device good results was achieved in 95.9% of patients who obtained the balloon-expandable Sapien XT and in 77.five% of patients who received the self-expandable CoreValve (relative threat, one.24 95% CI, one.twelve-one.37 P&lt0.001). The investigators attributed this variation to a substantial reduction in a lot more-than-mild aortic regurgitation (four.one% vs. 18.three% RR, .23 95% CI, .09-.58 P&lt0 .001) and to a diminished need to have to implant far more than one valve (.eight% vs. 5.eight% P=.03) in the Sapien group.

There was no considerable variation in cardiovascular mortality at thirty days, bleeding and vascular problems, or in a combined safety endpoint. But a new pacemaker was essential less typically in the Sapien group (17.three% vs. 37.six% P=.001). Improvement in signs and symptoms and high quality-of-lifestyle measures were much more widespread in the Sapien group. The investigators speculated that the tighter seal of the balloon-expandable Sapien XT could account for some of the variations that emerged in the trial.

“This is a extremely dynamic discipline,” lead author Abdel-Wahab stated. “We now have new valves coming out that will almost certainly be even far better, but we do not have ample information about them but. These outcomes can help to inform the layout of long term gadgets.”

In an accompanying editorial, E. Murat Tuzcu and Samir Kapadia consider note of the positive aspects witnessed with the Sapien XT in the trial, such as the main endpoint of device success. They caution, nonetheless, that it “should not be interpreted as a surrogate for long-phrase outcomes such as death, stroke, and top quality of lifestyle.”

1st TAVR Comparison Trial Favors Sapien XT Over CoreValve

Survival Benefit for TAVR More than Surgical treatment in Large-Chance Individuals

Transcatheter aortic valve substitute (TAVR), which has been slowly and cautiously coming into the clinical arena, will probably get a massive boost from a new trial displaying a substantial mortality advtange for TAVR more than classic surgical procedure.

Final results from the U.S. CoreValve Substantial-Risk Review had been presented at the American College of Cardiology in Washington, DC, and published concurrently in the New England Journal of Medicine. In the trial, 795 sufferers with significant aortic stenosis who who had been at higher risk for surgical treatment had been randomized to surgical aortic valve substitute (SAVR) or TAVR with the Medtronic Medtronic CoreValve device.

The headline information is the improved mortality with TAVR. In the as-handled analysis, at one year the fee of death was 14.two% in the TAVR group versus 19.one% in the SAVR group, a variation that was hugely important for noninferiority (P&lt0.001) and that reached significance for superiority (P=.04). A equivalent pattern occurred in the intention-to-treat evaluation: At one year, the rates of death were 13.9% for TAVR and 18.7% for SAVR (P&lt0.001 for non inferiority P=.04 for superiority).

Nevertheless, for the critical secondary endpoint of main adverse cardiovascular and cerebrovascular events at thirty days or discharge, TAVR did not meet the prespecified criteria for superiority (8.2% for TAVR vs. ten.9% for SAVR P=.ten). At thirty days, the stroke price was four.9% in the TAVR group and six.2% in the surgical group (P=.46). At 1 year, the strokes were 8.8% and twelve.6%, respectively (P=.10).

A lot more pacemakers were implanted in the TAVR group at 1 12 months (22.three% vs. eleven.three% for SAVR), and the TAVR group had a lot more key vascular issues. But bleeding complications occurred more regularly in the surgical procedure group.

In an interview with Rick Lange and David Hillis on CardioExchange, Columbia University interventional cardiologist Ajay Kirtane said that the trial “further tilts the stability toward TAVR in large-threat individuals.” He cautioned that it is unattainable at this stage to compare the CoreValve benefits with final results from the Sapien gadget in the Partner trials. “In the absence of a head-to-head comparison of the brief- and long-term functionality of these valves, it is truly challenging to speculate about valve-distinct distinctions, except theoretically,” he said. “I see this as a ‘win’ for TAVR as a complete.”

Survival Benefit for TAVR More than Surgical treatment in Large-Chance Individuals